Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.
Todd N, McNally R, Alqudah A, Jerotic D, Suvakov S, Obradovic D, Hoch D, Hombrebueno JR, Campos GL, Watson CJ, Gojnic-Dugalic M, Simic TP, Krasnodembskaya A, Desoye G, Eastwood KA, Hunter AJ, Holmes VA, McCance DR, Young IS, Grieve DJ, Kenny LC, Garovic VD, Robson T, McClements L. Todd N, et al. Among authors: robson t. J Clin Endocrinol Metab. 2021 Jan 1;106(1):26-41. doi: 10.1210/clinem/dgaa403. J Clin Endocrinol Metab. 2021. PMID: 32617576 Free PMC article.
FKBPL and SIRT-1 Are Downregulated by Diabetes in Pregnancy Impacting on Angiogenesis and Endothelial Function.
Alqudah A, Eastwood KA, Jerotic D, Todd N, Hoch D, McNally R, Obradovic D, Dugalic S, Hunter AJ, Holmes VA, McCance DR, Young IS, Watson CJ, Robson T, Desoye G, Grieve DJ, McClements L. Alqudah A, et al. Among authors: robson t. Front Endocrinol (Lausanne). 2021 Jun 2;12:650328. doi: 10.3389/fendo.2021.650328. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34149611 Free PMC article.
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh S, McCarthy HO, O'Neill E, Clarke RB, Robson T. McClements L, et al. Among authors: robson t. Clin Cancer Res. 2013 Jul 15;19(14):3881-93. doi: 10.1158/1078-0432.CCR-13-0595. Epub 2013 Jun 5. Clin Cancer Res. 2013. PMID: 23741069
FKBPL is a critical antiangiogenic regulator of developmental and pathological angiogenesis.
Yakkundi A, Bennett R, Hernández-Negrete I, Delalande JM, Hanna M, Lyubomska O, Arthur K, Short A, McKeen H, Nelson L, McCrudden CM, McNally R, McClements L, McCarthy HO, Burns AJ, Bicknell R, Kissenpfennig A, Robson T. Yakkundi A, et al. Among authors: robson t. Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):845-54. doi: 10.1161/ATVBAHA.114.304539. Epub 2015 Mar 12. Arterioscler Thromb Vasc Biol. 2015. PMID: 25767277 Free PMC article.
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L, Annett S, Yakkundi A, O'Rourke M, Valentine A, Moustafa N, Alqudah A, Simões BM, Furlong F, Short A, McIntosh SA, McCarthy HO, Clarke RB, Robson T. McClements L, et al. Among authors: robson t. BMC Cancer. 2019 Apr 11;19(1):351. doi: 10.1186/s12885-019-5500-0. BMC Cancer. 2019. PMID: 30975104 Free PMC article.
FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
Annett S, Moore G, Short A, Marshall A, McCrudden C, Yakkundi A, Das S, McCluggage WG, Nelson L, Harley I, Moustafa N, Kennedy CJ, deFazio A, Brand A, Sharma R, Brennan D, O'Toole S, O'Leary J, Bates M, O'Riain C, O'Connor D, Furlong F, McCarthy H, Kissenpfennig A, McClements L, Robson T. Annett S, et al. Among authors: robson t. Br J Cancer. 2020 Feb;122(3):361-371. doi: 10.1038/s41416-019-0649-5. Epub 2019 Nov 27. Br J Cancer. 2020. PMID: 31772325 Free PMC article.
244 results